The Bio Report Levine Media Group

Sam Murphy, CEO of SalubrisBio, discusses the challenges of pursuing complex diseases with complex therapies, its pipeline, and how its China-based parent has provided it financial freedom from the vagaries of the capital markets.

John Lewis, founder and CEO of Aegis Life, discusses the global need to address infectious diseases, the company’s platform technology, and how it is leveraging that to address the barriers to the delivery of vaccines and antibody therapies in developing economies.

Jay Hartenbach, chief operating officer of Diakonos Oncology, discusses the company’s dendritic cell cancer vaccine technology, how it works, and why its lead indication is an aggressive form of brain cancer.

James Porter, CEO of Nuvalent, discusses how the company designs drugs that address the challenges of both kinase resistance and selectivity, its pipeline in development, and why it’s critical that its experimental therapy for non-small cell lung cancer can penetrate the brain.

Bobby Azamian, CEO of Tarsus, discusses Lyme disease, the case for the company’s experimental prophylactic drug TP-05, and why you may already have been using a form of the drug to protect a four-legged member of your household.

Jason Bock, CEO of CMTC, the joint venture between Resilience and MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of CAR-T therapies.